AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2901668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (400 mg per kilogram of body weight) every three weeks for one year
Number of subjects: 84
Study 2901668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 29278279 — intervention group
Group type: EXPERIMENTAL
Intervention: Camicinal 50 mg once-daily
Number of subjects: 58
Study 27421242 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 5 mg
Number of subjects: 555
Study 27421242 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 10 mg
Number of subjects: 555
Study 27421242 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 20 mg
Number of subjects: 555
Study 27421242 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (AZL) 40 mg
Number of subjects: 555
Study 27421242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 27421242 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OLM) 20 mg
Number of subjects: 555
Study 24103157 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin tissues (Group A)
Number of subjects: 103
Study 24103157 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin tissues thickened with allogenic membrane (Group B)
Number of subjects: 103
Study 24103157 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick tissues (Group C)
Number of subjects: 103
Study 24103157 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 103
Study 24103157 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group C
Number of subjects: 103
Study 24103157 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group B and Group C
Number of subjects: 103
Study 24569327 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of botulinum toxin into the pyloric sphincter muscle
Number of subjects: 60
Study 24569327 — intervention group
Group type: COMPARATOR
Intervention: Pyloroplasty
Number of subjects: 60
Study 16331103 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 resting blood pressure measurements taken in a non-medical setting
Number of subjects: 0
Study 16331103 — intervention group
Group type: COMPARATOR
Intervention: Clinic resting blood pressure measurements taken before seeing the physician
Number of subjects: 0
Study 12800457 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg/HCTZ 12.5 mg
Number of subjects: 597
Study 12800457 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/HCTZ 12.5 mg
Number of subjects: 597
Study 10569261 — intervention group
Group type: EXPERIMENTAL
Intervention: Abduction orthosis treatment initiated at approximately 4 months of age in 6 cases with persisting dysplasia
Number of subjects: 93
Study 10569261 — intervention group
Group type: COMPARATOR
Intervention: No treatment (87 children)
Number of subjects: 93
Study 10569261 — intervention group
Group type: EXPERIMENTAL
Intervention: Abduction orthosis treatment
Number of subjects: 93
Study 7556835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone
Number of subjects: 200
Study 7556835 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g cefuroxime + 0.5 g metronidazole
Number of subjects: 200
Study 1974503 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 107
Study 7296744 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (n = 9)
Number of subjects: 17
Study 7296744 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise, n = 8)
Number of subjects: 17
Study 7296744 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after 2 weeks
Number of subjects: 17
Study 29383480 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT-A prostatic injection (200 UI)
Number of subjects: 127
Study 29383480 — intervention group
Group type: COMPARATOR
Intervention: Optimized medical therapy
Number of subjects: 127
Study 29083439 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (DHA 800 mg and EPA 225 mg daily for 3 years)
Number of subjects: 183
Study 29083439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules comprising liquid paraffin oil)
Number of subjects: 183
Study 26266835 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent perfluorodecalin (PFD) infused patch with Q-switched Alexandrite laser (755 nm)
Number of subjects: 17
Study 26266835 — intervention group
Group type: COMPARATOR
Intervention: Control side treated with one pass of standard Q-switched Alexandrite laser (755 nm)
Number of subjects: 17
Study 24185285 — intervention group
Group type: EXPERIMENTAL
Intervention: MIAU curriculum (Mental Illness Among Us)
Number of subjects: 250
Study 24185285 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (Control)
Number of subjects: 250
Study 21386089 — intervention group
Group type: EXPERIMENTAL
Intervention: NEVO sirolimus-eluting stent (NEVO SES)
Number of subjects: 100
Study 21386089 — intervention group
Group type: COMPARATOR
Intervention: TAXUS Liberté paclitaxel-eluting stent (TAXUS Liberté PES)
Number of subjects: 100
Study 18192468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tris-acryl gelatin microspheres
Number of subjects: 53
Study 18192468 — intervention group
Group type: COMPARATOR
Intervention: PVA microspheres
Number of subjects: 53
Study 15845718 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (NS; 0.9% NaCl)
Number of subjects: 51
Study 15845718 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 51
Study 12875455 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical conjunctival bridge flap technique
Number of subjects: 500
Study 12875455 — intervention group
Group type: COMPARATOR
Intervention: Bare sclera technique
Number of subjects: 500
Study 10540136 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (group 1; n = 10)
Number of subjects: 20
Study 10540136 — intervention group
Group type: COMPARATOR
Intervention: No thoracic epidural analgesia (group 2; n = 10)
Number of subjects: 20
Study 8862087 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured cases (late rotation)
Number of subjects: 0
Study 8862087 — intervention group
Group type: COMPARATOR
Intervention: Structured cases (late rotation)
Number of subjects: 0
Study 8862087 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured cases (early rotation)
Number of subjects: 0
Study 8862087 — intervention group
Group type: COMPARATOR
Intervention: Structured cases (early rotation)
Number of subjects: 0
Study 1746458 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg once daily
Number of subjects: 30
Study 1746458 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg once daily
Number of subjects: 30
Study 1746458 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 20 mg four times daily
Number of subjects: 30
Study 1746458 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg once daily (follow-up)
Number of subjects: 30
Study 6755255 — intervention group
Group type: EXPERIMENTAL
Intervention: Less intense anticoagulant therapy (mean prothrombin time of 26.9 seconds, Simplastin time 15 seconds)
Number of subjects: 96
Study 6755255 — intervention group
Group type: COMPARATOR
Intervention: More intense anticoagulant therapy (mean Simplastin time of 19.4 seconds, prothrombin time 41 seconds)
Number of subjects: 96
Study 6755255 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (less intense and more intense therapy)
Number of subjects: 96
Study 31996555 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-type catheter
Number of subjects: 70
Study 31996555 — intervention group
Group type: COMPARATOR
Intervention: Through-the-needle catheter
Number of subjects: 70
Study 30513231 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant and non-stimulant treatments for ADHD
Number of subjects: 0
Study 30513231 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD-specific drugs combined with SUD treatments
Number of subjects: 0
Study 30513231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatments for ADHD
Number of subjects: 0
Study 28041770 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Expert Feedback (DEF)
Number of subjects: 71
Study 28041770 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised Video Feedback (UVF)
Number of subjects: 71
Study 25435406 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube (ET)‐assisted technique from the mouth
Number of subjects: 56
Study 25435406 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique from the nostril (control group)
Number of subjects: 56
Study 24997499 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (n=24)
Number of subjects: 49
Study 24997499 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=25)
Number of subjects: 49
Study 22413938 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 200 mg bid
Number of subjects: 1203
Study 22413938 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1203
Study 19589009 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for patients and PCPs (face-to-face education for PCPs, letters and automated calls for patients)
Number of subjects: 1867
Study 19589009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 1867
Study 19589009 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for patients and PCPs
Number of subjects: 1867
Study 17334256 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated catheters
Number of subjects: 577
Study 17334256 — intervention group
Group type: COMPARATOR
Intervention: Standard catheters
Number of subjects: 577
Study 15213060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic NaCl solution infusion (855 mmol/l) followed by free access to water
Number of subjects: 16
Study 15213060 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 16
Study 11579072 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (twice weekly Osteofit classes for 10 weeks)
Number of subjects: 79
Study 11579072 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 11189212 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam
Number of subjects: 124
Study 11189212 — intervention group
Group type: COMPARATOR
Intervention: ticarcillin/clavulanic acid
Number of subjects: 124
Study 7653793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia (1% end‐tidal isoflurane and nitrous oxide in oxygen)
Number of subjects: 17
Study 7653793 — intervention group
Group type: COMPARATOR
Intervention: Propofol/alfentanil anaesthesia (propofol 2 mg/kg, alfentanil 15 micrograms/kg, maintained by infusion of propofol and alfentanil)
Number of subjects: 17
Study 2744287 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist intervention
Number of subjects: 114
Study 2744287 — intervention group
Group type: COMPARATOR
Intervention: No checklist (Control)
Number of subjects: 114
Study 2744287 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Checklist and Control)
Number of subjects: 114
Study 903059 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg Benzbromarone
Number of subjects: 0
Study 903059 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg Benzbromarone
Number of subjects: 0
Study 30972484 — intervention group
Group type: EXPERIMENTAL
Intervention: Herring (HER)
Number of subjects: 93
Study 30972484 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon (SAL)
Number of subjects: 93
Study 30972484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod (COD)
Number of subjects: 93
Study 30972484 — intervention group
Group type: COMPARATOR
Intervention: Milk (CAS, a casein-whey mixture as positive control)
Number of subjects: 93
Study 30972484 — intervention group
Group type: COMPARATOR
Intervention: Milk (CAS)
Number of subjects: 93
Study 30972484 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 93
Study 31622142 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care informational interventions (flyers and posters encouraging vaccination) during a 3-month intervention period.
Number of subjects: 8837
Study 31622142 — intervention group
Group type: COMPARATOR
Intervention: Usual care during a 4-month control period.
Number of subjects: 8837
Study 29316016 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% zinc sulfate shower gel (n=20)
Number of subjects: 30
Study 29316016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 30
Study 29316016 — intervention group
Group type: COMPARATOR
Intervention: Control (n=20)
Number of subjects: 30
Study 25922978 — intervention group
Group type: COMPARATOR
Intervention: 30 ml bupivacaine
Number of subjects: 68
Study 25922978 — intervention group
Group type: COMPARATOR
Intervention: 30 ml bupivacaine with 100 μg of fentanyl
Number of subjects: 68
Study 25922978 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml bupivacaine with 100 ng naloxone
Number of subjects: 68
Study 25922978 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml bupivacaine with 100 μg of fentanyl and 100 ng naloxone
Number of subjects: 68
Study 23102518 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) standard-dose for 12 weeks
Number of subjects: 58
Study 23102518 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls matched by age)
Number of subjects: 58
Study 22030144 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter (30 mL)
Number of subjects: 824
Study 22030144 — intervention group
Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2 gel
Number of subjects: 824
Study 20183354 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person formative SP examination
Number of subjects: 0
Study 20183354 — intervention group
Group type: COMPARATOR
Intervention: Web-based formative SP examination
Number of subjects: 0
Study 20183354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formats (in-person and web-based)
Number of subjects: 0
Study 17053181 — intervention group
Group type: EXPERIMENTAL
Intervention: sNMES (surface neuromuscular electrical stimulation)
Number of subjects: 176
Study 17053181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 17053181 — intervention group
Group type: EXPERIMENTAL
Intervention: sNMES
Number of subjects: 176
Study 12722173 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy for 3 weeks during a 20-week spa period
Number of subjects: 31
Study 12722173 — intervention group
Group type: COMPARATOR
Intervention: Non-spa period (control)
Number of subjects: 31
Study 12722173 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 31
Study 11712398 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 0
Study 11712398 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 0
Study 9189963 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.75 mg.kg‐1 by mouth)
Number of subjects: 107
Study 9189963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml of water)
Number of subjects: 107
Study 9189963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 1552106 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (100 mg with an initial bolus dose of 15 mg followed by an infusion of 50 mg over 30 min and 35 mg over 60 min)
Number of subjects: 421
Study 1552106 — intervention group
Group type: COMPARATOR
Intervention: APSAC
Number of subjects: 421
Study 1552106 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 421
Study 3910726 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 at 1.0 mg/kg per h
Number of subjects: 9
Study 3910726 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 at 2.5 mg/kg per h
Number of subjects: 9
Study 3910726 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (control)
Number of subjects: 9
Study 3910726 — intervention group
Group type: EXPERIMENTAL
Intervention: H142 (1.0 and 2.5 mg/kg per h)
Number of subjects: 9
Study 31162856 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening, 5 annual rounds
Number of subjects: 4052
Study 31162856 — intervention group
Group type: COMPARATOR
Intervention: Control arm (X-ray screening)
Number of subjects: 4052
Study 29078037 — intervention group
Group type: COMPARATOR
Intervention: Single-dose IV bococizumab (0.3, 1, 3, 6, 12, or 18 mg/kg)
Number of subjects: 188
Study 29078037 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose IV bococizumab (0.5 or 4 mg/kg) added to ongoing atorvastatin 40 mg/day
Number of subjects: 188
Study 29078037 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose fixed SC bococizumab (100 or 200 mg) or IV bococizumab (200 mg)
Number of subjects: 188
Study 29078037 — intervention group
Group type: COMPARATOR
Intervention: Weekly IV bococizumab (0.25, 0.5, 1, or 1.5 mg/kg)
Number of subjects: 188
Study 27669019 — intervention group
Group type: EXPERIMENTAL
Intervention: DECEPTION group (unaware of SS literature)
Number of subjects: 28
Study 27669019 — intervention group
Group type: COMPARATOR
Intervention: BIASED group (aware of SS literature)
Number of subjects: 28
Study 27669019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 27669019 — intervention group
Group type: COMPARATOR
Intervention: BIASED group
Number of subjects: 28
Study 27669019 — intervention group
Group type: EXPERIMENTAL
Intervention: DECEPTION group
Number of subjects: 28
Study 24786469 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated, humidified, high‐flow nasal cannula (HHHFNC)
Number of subjects: 20
Study 24786469 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airways pressure (NCPAP)
Number of subjects: 20
Study 22182053 — intervention group
Group type: EXPERIMENTAL
Intervention: WBI-1001 0.5%
Number of subjects: 148
Study 22182053 — intervention group
Group type: EXPERIMENTAL
Intervention: WBI-1001 1.0%
Number of subjects: 148
Study 22182053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 20889939 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine + Saline (Group L)
Number of subjects: 60
Study 20889939 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine + Dexmedetomidine (Group LD)
Number of subjects: 60
Study 17939171 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg single dose)
Number of subjects: 0
Study 17939171 — intervention group
Group type: COMPARATOR
Intervention: Commercially available solid oral dosage pharmaceutical formulations (tablets)
Number of subjects: 0
Study 16099718 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g sodium oxybate nightly for 8 weeks
Number of subjects: 228
Study 16099718 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g sodium oxybate nightly for 8 weeks
Number of subjects: 228
Study 16099718 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g sodium oxybate nightly for 8 weeks
Number of subjects: 228
Study 16099718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 12384207 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom (FC) use
Number of subjects: 330
Study 10443596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitecapone (cardioplegia supplemented with nitecapone)
Number of subjects: 30
Study 10443596 — intervention group
Group type: COMPARATOR
Intervention: Control (crystalloid cardioplegia)
Number of subjects: 30
Study 10443596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitecapone
Number of subjects: 30
Study 10443596 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 8578179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 6 weeks
Number of subjects: 31
Study 8578179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2364570 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied 1 hour prior to infiltration
Number of subjects: 2
Study 2364570 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied 1 hour prior to infiltration
Number of subjects: 2
Study 2364570 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA applied to one lesion and placebo to another lesion
Number of subjects: 2
Study 2364570 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to one lesion and EMLA to another lesion
Number of subjects: 2
Study 383276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 IV on day 1 plus DTIC 200 mg/m2 IV days 1 through 5
Number of subjects: 120
Study 383276 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 600 mg/m2 IV on day 1 plus DTIC 200 mg/m2 IV days 1 through 5 plus C. parvum 5 mg/m2 IV on day 8 and day 15
Number of subjects: 120
Study 7036710 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 57
Study 7036710 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 57
Study 31190442 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for pediatric acute myeloid leukemia (AML)
Number of subjects: 348
Study 31190442 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 348
Study 30021671 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid complex (50 mg) + 50 mg oil palm-derived vitamin E + unrestricted palm-derived water-soluble antioxidants
Number of subjects: 40
Study 30021671 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 30021671 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg d-α-tocopheryl acetate
Number of subjects: 40
Study 30021671 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oil palm-derived vitamin E
Number of subjects: 40
Study 30021671 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted water-soluble antioxidants
Number of subjects: 40
Study 26771270 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 150
Study 26771270 — intervention group
Group type: COMPARATOR
Intervention: Psoas Compartment Block (PCB)
Number of subjects: 150
Study 24695896 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ (20 μg/d)
Number of subjects: 125
Study 24695896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125